ICMR says no to use of Hydroxycholoroquine, Ivermectin for Covid

By: |
September 25, 2021 2:30 AM

Global health experts have been warning against the use of these drugs to treat Covid-19, as there was no evidence of its therapeutic effect against Covid-19.

Remdesivir has been suggested for moderate Covid-19 cases and Tocilizumab continue to be on the list for severe Covid cases and within 24-48 hours of the onset of the severe disease or ICU admission.Remdesivir has been suggested for moderate Covid-19 cases and Tocilizumab continue to be on the list for severe Covid cases and within 24-48 hours of the onset of the severe disease or ICU admission.

The Indian Council of Medical Research’s (ICMR) Covid-19 Task Force Joint Monitoring Group has stopped the usage of Hydroxycholoroquine and Ivermectin for treating Covid-19 patients in the country. Global health experts have been warning against the use of these drugs to treat Covid-19, as there was no evidence of its therapeutic effect against Covid-19.

These two drugs were no longer part of the revised clinical guidance for management of adult Covid-19 in the country. The Directorate General of Health Services under the ministry of health had in May issued guidelines to stop the use of Ivermectin and HCQ and now ICMR has dropped these two drugs. Remdesivir has been suggested for moderate Covid-19 cases and Tocilizumab continue to be on the list for severe Covid cases and within 24-48 hours of the onset of the severe disease or ICU admission.

As per the new guidelines, treatment for patients with moderate disease with SpO2 level 92-93% and breathlessness has to be with anti-inflammatory and anticoagulation drugs. Remdesivir is to be considered only in patients with moderate to severe disease requiring supplemental oxygen and with no renal or hepatic dysfunction. It is not be used in patients who are not on oxygen support in home settings.

For the severe infection with SpO2 level less than 90%, the treatment as per the guidelines is anticoagulation drugs and anti-inflammatory or immunomodulatory therapy. Tocilizumab is to be considered if there was no improvement despite use of steroids and severe disease. It is to given to the patient within 24 to 48 hours of onset of severe disease or ICU admission.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Delhi sees 25 new COVID-19 cases, zero fatality; positivity rate dips to 0.04%
2Govt looking to vaccinate country’s entire adult population by year-end: MoS Health Bharati Pravin Pawar
3Covid-19: Gujarat, Rajasthan, Jharkhand under-reported cases, deaths, new study finds